
GE HealthCare Technologies Inc.
GEHCNASDAQHealthcareMedical - Devices
前收盘价
US$74.82
+US$0.76 · +1.03%
盘前
US$74.94
+US$0.12 · +0.16%
8月24日 4:25 ET
GEHC公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Buy
Favorable setup — positive multi-factor alignment
估值
84
Deep Value
动量
34
Weakening
情绪
63
Bullish
风险韧性
66
Moderate Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- 行业
- Medical - Devices
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Peter J. Arduini
- 上市以来
- 2022年12月15日
- 雇员
- 54,000
市场位置
日内区间
当前US$74.82,
52周区间
当前US$74.82,
- 开盘价
- US$74.23
- 前收盘价
- US$74.06
- 成交量
- 224.75万
- 0.44× 平均值
- 平均成交量
- 512.85万
- 日均成交量
- 市值
- 337.95亿 USD
- 贝塔
- 0.82
- 市场参考 1
- 50天平均值
- US$66.6559
- 高于平均水平+12.25%
- 200天平均值
- US$72.8386
- 高于平均水平+2.72%
财务数据
财务快照
最近十二个月估值与收益率
- 市盈率(TTM)
- 21.5×
- 市净率(TTM)
- 3.09×
- 市销率(TTM)
- 1.67×
- 股息率
- 0.19%
盈利能力和效率
- 毛利率
- 42.90%
- 营业利润率
- 12.70%
- 净利润率
- 7.86%
财务健康
- 负债权益比
- 0.92×
- 奥特曼 Z 分数
- 1.77
- 皮奥特罗斯基 F 分数
- 5 共 9 个
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 206.25亿 USD | 196.72亿 USD | 195.52亿 USD | 183.41亿 USD | 175.85亿 USD |
| 销货成本 | 123.78亿 USD | 114.67亿 USD | 116.3亿 USD | 111.62亿 USD | 104.11亿 USD |
| 毛利 | 82.47亿 USD | 82.05亿 USD | 79.22亿 USD | 71.79亿 USD | 71.74亿 USD |
| 研究与开发 | 12.6亿 USD | 13.11亿 USD | 12.05亿 USD | 10.26亿 USD | 8.16亿 USD |
| 销售、一般及管理费用 | 42.25亿 USD | 42.69亿 USD | 42.82亿 USD | 36.31亿 USD | 35.63亿 USD |
| 营业费用 | 54.85亿 USD | 55.8亿 USD | 54.87亿 USD | 46.57亿 USD | 43.79亿 USD |
| 利息收入 | — | — | 2600万 USD | — | 3400万 USD |
| 利息支出 | 4.5亿 USD | 5.05亿 USD | 5.42亿 USD | 8600万 USD | 4000万 USD |
| 折旧和摊销 | 5.78亿 USD | 5.8亿 USD | 6.1亿 USD | 6.33亿 USD | 6.25亿 USD |
| 营业利润 | 27.62亿 USD | 26.25亿 USD | 24.35亿 USD | 25.22亿 USD | 27.95亿 USD |
| 净利润 | 20.84亿 USD | 19.93亿 USD | 15.68亿 USD | 19.16亿 USD | 22.47亿 USD |
公司数据更新于 2026年8月24日。
GEHC 消息
GEHC同业公司
继续GoAI的研究
在 GoAI 中研究GEHCresearch.disclaimer











